R.J. Buka; D. Moloney
Description
Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generall
...
y shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine. Table of Contents: • DLBCL: an overview • CAR T cells • CAR T-cell products • Delivering CAR T-cell therapy and managing patient expectations • CAR T-cell therapy-related toxicities
Read more
Genres
Medical & Healthcare
Tags
Medical
Allied Health & Medical
Hematology
Reading Moods
Adventurous & Action-Packed
Contributors
No contributors specified
Publishing Info
Publisher
S. Karger AG (Switzerland)
Month-Year
Sep, 2021
ISBN
ISBN-13: 9783318069358
ISBN-10: 3318069353
Language
English
No. of Pages
96
Format
E-book
Awards & Recognition
No awards specified
Available at
No purchase options available
First Reviewed by
Claim the Book
Are you an author of this book?
Report
Found an issue or correction?